AmerisourceBergen (ABC) and Its Rivals Critical Survey

AmerisourceBergen (NYSE: ABC) is one of 256 public companies in the “MED PRODS” industry, but how does it contrast to its competitors? We will compare AmerisourceBergen to similar companies based on the strength of its profitability, earnings, dividends, risk, analyst recommendations, institutional ownership and valuation.

Risk & Volatility

How to Become a New Pot Stock Millionaire

AmerisourceBergen has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, AmerisourceBergen’s competitors have a beta of 0.96, meaning that their average share price is 4% less volatile than the S&P 500.

Insider and Institutional Ownership

67.3% of AmerisourceBergen shares are owned by institutional investors. Comparatively, 52.1% of shares of all “MED PRODS” companies are owned by institutional investors. 27.3% of AmerisourceBergen shares are owned by insiders. Comparatively, 15.5% of shares of all “MED PRODS” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


AmerisourceBergen pays an annual dividend of $1.52 per share and has a dividend yield of 1.8%. AmerisourceBergen pays out 25.9% of its earnings in the form of a dividend. As a group, “MED PRODS” companies pay a dividend yield of 0.9% and pay out 22.0% of their earnings in the form of a dividend. AmerisourceBergen has raised its dividend for 13 consecutive years.

Earnings & Valuation

This table compares AmerisourceBergen and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
AmerisourceBergen $153.14 billion $364.48 million 14.66
AmerisourceBergen Competitors $3.69 billion $127.47 million -49.30

AmerisourceBergen has higher revenue and earnings than its competitors. AmerisourceBergen is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares AmerisourceBergen and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AmerisourceBergen 0.66% 53.65% 3.82%
AmerisourceBergen Competitors -704.80% -110.16% -15.61%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for AmerisourceBergen and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AmerisourceBergen 0 5 10 0 2.67
AmerisourceBergen Competitors 1090 4530 8464 279 2.55

AmerisourceBergen presently has a consensus target price of $104.38, suggesting a potential upside of 21.08%. As a group, “MED PRODS” companies have a potential upside of 12.52%. Given AmerisourceBergen’s stronger consensus rating and higher possible upside, equities research analysts clearly believe AmerisourceBergen is more favorable than its competitors.


AmerisourceBergen beats its competitors on 13 of the 15 factors compared.

About AmerisourceBergen

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment provides pharmaceutical distribution and other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers. The company's Other segment provides commercialization support services, including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers; specialty transportation and logistics services for the biopharmaceutical industry; and animal health care products. It markets its products and services through independent sales forces and marketing organizations. AmerisourceBergen Corporation was founded in 1985 and is headquartered in Chesterbrook, Pennsylvania.

Receive News & Ratings for AmerisourceBergen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AmerisourceBergen and related companies with's FREE daily email newsletter.

Leave a Reply